Financials data is unavailable for this security.
View more
Year on year Beijing Biostar Pharmaceuticals Co Ltd had net income fall 18.15% from a loss of 160.51m to a larger loss of 189.64m despite a 103.03% increase in revenues from 32.82m to 66.64m. An increase in the cost of goods sold as a percentage of sales from 27.24% to 29.73% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Beijing Biostar Pharmaceuticals Co Ltd fell by 22.02m. However, Cash Flow from Investing totalled 129.83m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 149.33m for operations while cash used for financing totalled 1.13m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in CNYView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
